1009119-65-6

• 常用中文名：达卡他韦二盐酸盐
• 常用英文名：Daclatasvir dihydrochloride
• CAS号：1009119-65-6
• 分子式：C₄₀H₅₂Cl₂N₈O₆
• 分子量：811.797
• 相关类别： 信号通路 抗感染 HCV
• 发布时间：2018-09-25 15:04:11
• 更新时间：2024-01-03 01:19:23
• Daclatasvir(BMS-790052)是HCV NS5A高度选择性抑制剂,EC50为9-50 pM。

名称

• 中文名: 达卡他韦二盐酸盐
• 英文名: daclatasvir hydrochloride
• 中文别名: N,N’-[[1,1’-联苯]-4,4’-二基双[1H-咪唑-5,2-二基-(2S)-2,1-吡咯烷二基[(1S)-1-(1-甲基乙基)-2-氧代-2,1-乙烷二基]]]二氨基甲酸二甲酯二盐酸盐
• 英文别名: Daclatasvir dihydrochloride (USAN); daclatasvir hydrochloride; Carbamic acid, N,N'-[[1,1'-biphenyl]-4,4'-diylbis[1H-imidazole-5,2-diyl(2S)-2,1-pyrrolidinediyl[(1S)-1-(1-methylethyl)-2-oxo-2,1-ethanediyl]]]bis-, dimethyl ester, hydrochloride (1:2); BMS-790052 dihydrochloride; UNII-50ZO25C11D; methyl N-[(2S)-1-[(2S)-2-[5-[4-[4-[2-[(2S)-1-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]pyrrolidin-2-yl]-1H-imidazol-5-yl]phenyl]phenyl]-1H-imidazol-2-yl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate,dihydrochloride; MFCD18251440; Daklinza; CS-0270; Daclatasvir dihydrochloride; Daclatasvir hydrochloride (JAN); Daclatasvir HCL; Methyl [(2S)-1-{(2S)-2-[4-(4'-{2-[(2S)-1-{(2S)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl}-2-pyrrolidinyl]-1H-imidazol-4-yl}-4-biphenylyl)-1H-imidazol-2-yl]-1-pyrrolidinyl}-3-methyl-1-oxo-2-butanyl]carbamate dihydrochloride; BMS 790052; Daclatasvir (dihydrochloride)

物化性质

• 分子式: C₄₀H₅₂Cl₂N₈O₆
• 分子量: 811.797
• 精确质量: 810.338684
• PSA: 181.62000
• LogP: 8.11060
• 外观性状: 白色至类白色固体
• 储存条件: 2-8℃，干燥

生物活性

• 描述: Daclatasvir(BMS-790052)是HCV NS5A高度选择性抑制剂,EC50为9-50 pM。
• 相关类别:
  信号通路 >> 代谢酶/蛋白酶 >> HCV蛋白酶
  信号通路 >> 抗感染 >> HCV
  研究领域 >> 感染
• 参考文献:

  [1]. Suzuki F, Sezaki H, Akuta N, Suzuki Y, Seko Y, Kawamura Y, Hosaka T, Kobayashi M, Saito S, Arase Y, Ikeda K, Kobayashi M, Mineta R, Watahiki S, Miyakawa Y, Kumada H.Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b.J Clin Virol. 2012 Aug;54(4):352-4. Epub 2012 Jun 1.

  [2]. Jiang H, Zeng J, Kandoussi H, Liu Y, Wang X, Bifano M, Cojocaru L, Ryan J, Arnold ME.A sensitive and accurate liquid chromatography-tandem mass spectrometry method for quantitative determination of the novel hepatitis C NS5A inhibitor BMS-790052 (daclastasvir) in human plasma and urine.J Chromatogr A. 2012 Jul 6;1245:117-21. Epub 2012 May 14.

  [3]. Sun JH, O'Boyle Ii DR, Zhang Y, Wang C, Nower P, Valera L, Roberts S, Nettles RE, Fridell RA, Gao M.Impact of a baseline polymorphism on the emergence of resistance to the hepatitis C virus nonstructural protein 5A replication complex inhibitor, BMS-790052.Hepatology. 2012 Jun;55(6):1692-9.

  [4]. Wang C, Jia L, Huang H, Qiu D, Valera L, Huang X, Sun JH, Nower PT, O'Boyle DR 2nd, Gao M, Fridell RA.In vitro activity of BMS-790052 on hepatitis C virus genotype 4 NS5A.Antimicrob Agents Chemother. 2012 Mar;56(3):1588-90. Epub 2011 Dec 27.

  [5]. Fridell RA et al. Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system. Antimicrob Agents Chemother. 2010 Sep;54(9):3641-50.

安全

• 危害码 (欧洲): Xn